Immune checkpoint inhibitors (ICIs) including programmed cell death 1 (PD1)/programmed cell death 1 ligand 1 (PD-L1)-specific monoclonal antibodies, seem to be more effective for female patients compared with male patients with melanoma (8). This evidence concerns the gene CD274 and melanoma.